Drug Delivery
(HSP) Hospira Incorporated – Bear of the Day
Hospira Inc.’s (HSP) third quarter preliminary results were below expectations due to continued manufacturing problems at the company’s Rocky Mountain facility. The facility is expected to continue functioning below full capacity through the remainder of 2011. The...
27Oct2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In...
1Sep2011 | vitalstocks | 0 comments | Continued(PETS) PetMed Still Underperforms
Recently, we reaffirmed our Underperform recommendation on PetMed Express (PETS) with a target price of $11.00. PetMed has been reporting disappointing results over the past few quarters. Lower revenues coupled with higher operating expenses had a negative impact on margins....
5Jul2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Presents Encouraging Data
Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32). ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole). ...
1Jul2011 | vitalstocks | 0 comments | Continued(PETS) PetMed Express – Bear of the Day
PetMed Express (PETS) reported a disappointing quarter with EPS of $0.19, missing the Zacks Consensus Estimate of $0.22 and the year-ago quarter’s $0.27. While new order sales declined on fewer new customers, revenues increased 1.2% to $50.9 million. Both gross and operating...
1Jul2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Evenly Poised
We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS)...
24Jun2011 | vitalstocks | 0 comments | Continued(PETS) PetMed Express – Bear of the Day
PetMed Express (PETS) reported a disappointing quarter with EPS of $0.19 missing the Zacks Consensus Estimate of $0.22 and the year-ago quarter’s $0.27. Both gross and operating margins declined due to higher product and advertising costs — a big blow for the company...
16May2011 | vitalstocks | 0 comments | Continued(ALKS) Stock Market News for May 10, 2011 – Market News
After suffering a slump last week, commodities made a strong comeback yesterday and lifted the benchmarks higher. Energy shares joined in on the uptrend as crude prices once again rose above $100 per barrel. Meanwhile fresh worries about Greece’s credit ratings partially limited...
10May2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermesto Buy Elan Unit for $960 Million
Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately...
9May2011 | vitalstocks | 0 comments | Continued(HSP) Hospira Earnings Beat The Street – Backs Outlook
Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version of Sanofi Aventis’ (SNY) cancer drug Taxotere which was launched in...
3May2011 | vitalstocks | 0 comments | Continued(ALKS) Company News for April 18, 2011 – Corporate Summary
• Chesapeake Energy Corp’s. (NYSE:CHK) share prices gained 0.25% after it announced plans to buy Bronco Drilling Co. (NASDAQ:BRNC) for $11 a share. The purchase price represents a 24% premium over Bronco’s average 90-day closing price • A report from Bloomberg cited...
18Apr2011 | vitalstocks | 0 comments | Continued(ALKS) Alkermes 2010 Second Quarter Revenues Rise – View Lowered
Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was a loss of 15 cents per share. The narrower-than-expected loss was attributable...
24Nov2010 | vitalstocks | 0 comments | Continued(ELN) Elan Quarterly Report Matches Earnings Estimates
Elan Corporation plc (ELN) reported loss per share of 7 cents for the third quarter of 2010, in line with the Zacks Consensus Estimate but way below the year-ago earnings of 11 cents per share. The year-ago quarter saw Elan recording a divestment gain of $107.7 million, which...
3Nov2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes’ Vivitrol Earns US Food and Drug Administration Clearance
Alkermes Inc. (ALKS) received a boost when the US Food and Drug Administration (FDA) cleared its drug Vivitrol (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence after opioid detoxification. Opioid dependence refers to a...
17Oct2010 | vitalstocks | 0 comments | Continued(PETS) PetMed Express Incorporated – Bear of the Day
PetMed Express, Inc. (PETS) reported first-quarter fiscal 2011 EPS of $0.32, way below the Zacks Consensus Estimate of $0.38 and the year-ago quarter’s $0.36. The company witnessed a decline in revenues due to a lack of television remnant space availability at affordable...
18Aug2010 | vitalstocks | 0 comments | Continued(PETS) PetMed Express Incorporated – Bear of the Day
PetMed Express, Inc. (PETS) reported first-quarter fiscal 2011 EPS of $0.32, way below the Zacks Consensus Estimate of $0.38 and the year-ago quarter’s $0.36. The company witnessed a decline in revenues due to a lack of television remnant space availability at affordable...
18Aug2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Earnings Report Shows Revenues Dipped
Alkermes Inc.’s (ALKS) first-quarter fiscal 2011 net loss of 14 cents per share compared unfavorably with the year-ago loss of 2 cents per share. The Zacks Consensus Estimate was a loss of 14 cents per share. Quarterly Results Total revenues for the reported quarter declined...
10Aug2010 | vitalstocks | 0 comments | Continued(HSP) Hospira Second Quarter 2010 Earnings Preview
Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with an upside of 2.53%), compared with earnings of 73 cents per share in...
2Aug2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes, Amylin Pharmaceuticals, and Eli Lilly See Encouraging Data on Diabetes Candidate Bydureon
Recently Alkermes Inc. (ALKS), Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly & Co. (LLY), the co-developers of type II diabetes candidate Bydureon (exenatide once weekly), presented pooled safety data on the candidate. The companies presented the data at the 70th Annual...
29Jun2010 | vitalstocks | 0 comments | Continued(HSP) Hospira Extends Javelin Pharmaceuticals Aquisition Offer
Recently, Hospira (HSP) extended its tender offer for acquiring Javelin Pharmaceuticals (JAV). The offer, which was supposed to expire on May 18, has been extended till June 2, 2010 as all the conditions of the deal have not yet been met. Viewing the uncertainty surrounding the...
24May2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes’ Quarterly Earnings Report Shows Revenue Dip
Alkermes Inc. (ALKS) reported a fourth quarter fiscal 2010 net loss of 12 cents per share (excluding special items but including stock-based compensation) compared with a loss of 13 cents per share in the year-ago period; excluding the impact of the termination of collaboration...
17May2010 | vitalstocks | 0 comments | Continued(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit
I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when doctors...
29Apr2010 | InvestmentU | 0 comments | Continued(HSP) Hospira Announces Intentions to Acquire Javelin Pharmaceuticals
Recently, Hospira (HSP) announced its intention to acquire Javelin Pharmaceuticals (JAV) for $2.20 per share or approximately $145 million. Hospira expects to initiate the tender offer for all the outstanding shares of Javelin shortly. The acquisition of Javelin will provide...
21Apr2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Files New Drug Application For Vivitrol Expansion
Recently Alkermes, Inc. (ALKS) submitted a supplemental New Drug Application (sNDA) for Vivitrol (naltrexone for extended-release injectable suspension) to the US Food and Drug Administration (FDA) for treating opioid dependence. Opioid dependence refers to a chronic ailment...
14Apr2010 | vitalstocks | 0 comments | Continued(HSP) Hospira Settles Sanofi-Aventis Patent Dispute
Hospira (HSP) has reached an agreement with Sanofi-Aventis (SNY) to settle a patent dispute for the US sales of oxaliplatin injection, a generic version of Sanofi-Aventis’ Eloxatin. Per the settlement, Hospira will not sell oxaliplatin injection in the US until June 30,...
5Apr2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Drug Pipeline Advances
Recently, Alkermes Inc. (ALKS) initiated a multidose early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist, which has the potential to block the effects of opioid agonists on gastrointestinal motility, commonly termed...
19Mar2010 | vitalstocks | 0 comments | Continued(BVF) Biovail and Acadia Pharmaceuticals Continue Forward with Pimavanserin Study
Biovail (BVF) and Acadia Pharmaceuticals (ACAD) are moving forward with a 3-pronged strategy for pimavanserin. Acadia plans a phase III trial in Parkinson’s disease psychosis (PDP) and a phase II feasibility study in Alzheimer’s disease psychosis (ADP). Biovail plans a phase...
10Mar2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Drug Application Gets New Target Date
Recently, the U.S. Food and Drug Administration (FDA) announced that inclement weather has forced the agency to delay the review of the new drug application (NDA) of the type II diabetes candidate, exenatide once-weekly. Exenatide once-weekly is co-developed by Alkermes Inc....
1Mar2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Pipeline Announces Good News
Recently, Alkermes Inc. (ALKS) announced encouraging topline data from an early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist having the potential to block the effects of opioid agonists on gastrointestinal motility,...
17Feb2010 | vitalstocks | 0 comments | Continued(ALKS) Alkermes Retains Neutral Recommendation
We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism...
8Feb2010 | vitalstocks | 0 comments | Continued